US17322U2078 - Common Stock
CITIUS PHARMACEUTICALS INC
NASDAQ:CTXR (4/25/2024, 7:00:01 PM)
After market: 0.726 -0.01 (-0.9%)0.7326
+0.02 (+2.25%)
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 22 full-time employees. The company went IPO on 2017-08-03. The company develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Its Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Its Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Its NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome (ARDS).
CITIUS PHARMACEUTICALS INC
11 Commerce Dr Fl 1
Cranford NEW JERSEY 07016
P: 19089676677
CEO: Myron Holubiak
Employees: 22
Website: https://www.citiuspharma.com/
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Here you can normally see the latest stock twits on CTXR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: